Resources Contact Us Home
Browse by: INVENTOR PATENT HOLDER PATENT NUMBER DATE
 
 
Inventor:
Garst; Michael E.
Address:
Newport Beach, CA
No. of patents:
113
Patents:


1 2 3










Patent Number Title Of Patent Date Issued
8580817 1-(1-OXO-1,2,3,4-tetrahydroisoquinolin-7-YL)urea derivatives as N-formyl peptide receptor like-1 November 12, 2013
The present invention relates to novel 1-(1-Oxo-1,2,3,4-tetrahydroisoquinolin-7-yl)urea derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of the N-formyl peptide receptor like-1 (FPRL-1) receptor.
8580779 1,2-bis-sulfonamide derivatives as chemokine receptor modulators November 12, 2013
The present invention relates to novel bis-sulfonamide derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of chemokine receptors.
8258167 Naphthylmethylimidizoles as therapeutic agents September 4, 2012
Disclosed herein is a method of treating stress urinary incontinence comprising administering a compound to a mammal in need thereof, wherein said compound has the formula ##STR00001## Compositions and medicaments related thereto are also disclosed.
8193203 Bicyclic compounds having activity at the CXCR4 receptor June 5, 2012
A compound represented by the structural formula: ##STR00001## Therapeutic methods, compositions, and medicaments related thereto are also disclosed.
8183414 N-(1-phenyl-2-arylethyl)-4,5-dihydro-2H-pyrrol-5-amine compounds as subtype selective modulators May 22, 2012
The present invention provides compounds which are N-(1-phenyl-2-arylethyl)-4,5-dihydro-2H-pyrrol-5-amine compounds and are subtype selective modulators of alpha 2B or alpha 2B and alpha 2C adrenoreceptors and are selected from the group of compounds represented by the formula ##STR
8168795 Selective sphingosine-1-phosphate receptor antagonists May 1, 2012
Described herein are compounds useful as antagonists of sphingosine-1-phosphate receptors. Further described herein is the use of these compounds and related pharmaceutical compositions to treat disorders associated with sphingosine-1-phosphate-3 (S1P3) receptor modulation.
8168680 Cyclopentane heptan(ENE)OIC acid, 2-heteroarylalkenyl derivatives as therapeutic agents May 1, 2012
A compound comprising ##STR00001## or a pharmaceutically acceptable salt or a prodrug thereof, having the groups described in detail herein is disclosed. Also disclosed herein are compounds comprising ##STR00002## or derivatives thereof, or pharmaceutically acceptable salts, tetra
8124774 Therapeutic ((phenyl)imidazolyl)methylquinolinyl compounds February 28, 2012
Disclosed herein is a compound of the formula (I) therapeutic methods, compositions, and medicaments related thereto are also disclosed. ##STR00001##
8119807 Quinolynylmethylimidizoles as therapeutic agents February 21, 2012
Disclosed herein is a compound of the formula (I): (I). Therapeutic methods, compositions and medicaments related thereto are also disclosed. ##STR00001##
8071636 Methods of treating alpha adrenergic mediated conditions December 6, 2011
Described herein are compounds for and methods of treating conditions or diseases in a subject by administering to the subject a pharmaceutical composition containing an effective amount of an .alpha.-adrenergic modulator. The compounds and methods are also useful for alleviating typ
8063231 Methods of treating alpha adrenergic mediated conditions November 22, 2011
Described herein are novel N-(2 and/or 3-substituted benzyl)-4,5-dihydro-1H-imidazol-2-amine derivatives processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals modulators of subtype .alpha..sub.2B and/or .alpha..sub.2C adrenergic re
8063086 Imidazole-2-thiones November 22, 2011
Compounds of Formula 1 ##STR00001## where X is S and the variables have the meaning defined in the specification are specific or selective to alpha.sub.2B and/or alpha.sub.2C adrenergic receptors in preference over alpha.sub.2A adrenergic receptors, and as such have no or only minimal
8017655 Non-acidic cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic age September 13, 2011
The present invention provides cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl compounds, which may be substituted in the 1-position with amino, amido, ether or ester groups, e.g., a 1-OH cyclopentane heptanoic acid, 2-(cycloalkyl or arylalkyl) compound. The cyclopentane heptanoic
8013169 Naphthylmethylimidizoles as therapeutic agents September 6, 2011
Disclosed herein is a compound of the formula (a): Therapeutic methods, compositions and medicaments related thereto are also disclosed. ##STR00001##
7960423 Imidazole-2-thiones June 14, 2011
Compounds of Formula 1 ##STR00001## where X is S and the variables have the meaning defined in the specification are specific or selective to alpha.sub.2B and/or alpha.sub.2C adrenergic receptors in preference over alpha.sub.2A adrenergic receptors, and as such have no or only mi
7919630 Synthesis of imidazole 2-thiones via thiohydantoins April 5, 2011
The present invention provides a method of making an imidazole 2-thione which comprises the step(s) of reducing a thiohydantoin to said imidazole-2-thione.
7906552 Cyclopentane heptan(ENE)OIC acid, 2-heteroarylalkenyl derivatives as therapeutic agents March 15, 2011
A compound comprising ##STR00001## or a pharmaceutically acceptable salt or a prodrug thereof, having the groups described in detail herein is disclosed.Also disclosed herein are compounds comprising ##STR00002## or derivatives thereof, or pharmaceutically acceptable salts, tetrazoles,
7902247 Substituted-aryl-2-phenylethyl-1H-imidazole compounds as subtype selective modulators of alpha 2 March 8, 2011
A compound having selective modulating activity at the alpha 2B and/or alpha 2C adrenergic receptor subtypes is represented by the general Formula 1: ##STR00001## wherein n=1-4; X is C or N; R.sup.1-R.sup.6 can be the same or different and are independently selected from the group
7884244 Therapeutic fluoroethylcyano guanidines February 8, 2011
Disclosed herein is compound having a formula ##STR00001## as described herein. Therapeutic methods, compositions, and medicaments related thereto are also disclosed.
7880017 Process for the synthesis of imidazoles February 1, 2011
The present invention provides a process for the preparation of imidazoles by reacting a cyano compound with a silylalkylisocyanide compound. Such imidazoles are useful pharmacologically-active compounds and/or intermediates for the preparation of pharmacologically-active compounds.
7868020 Quinolynylmethylimidizoles as therapeutic agents January 11, 2011
Disclosed herein is a compound of the formula (I):(I). Therapeutic methods, compositions and medicaments related thereto are also disclosed. ##STR00001##
7863319 Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents January 4, 2011
A compound comprising ##STR00001## or a pharmaceutically acceptable salt or a prodrug thereof, having the groups described in detail herein is disclosed.Also disclosed herein are compounds comprising ##STR00002## or derivatives thereof, or pharmaceutically acceptable salts, tetrazoles,
7838545 4-(condensed cyclicmethyl)-imidazole-2-thiones acting as alpha2 adrenergic agonists November 23, 2010
Compounds of Formula 1 ##STR00001## where the variables have the meaning defined in the specification are agonists of alpha.sub.2 adrenergic receptors. Several compounds of the disclosure are specific or selective to alpha.sub.2B and/or alpha.sub.2C adrenergic receptors in prefere
7829587 Substituted 2-aminotetralin derivatives as selective alpha 2B agonist November 9, 2010
Substituted 2-aminotetralin derivatives as selective alpha 2B agonists can be incorporated in a pharmaceutical composition and can be used in methods of treating an alpha 2B receptor mediated diseases or conditions. The compounds are represented by Formula 1: ##STR00001## wherein
7795292 Unsubstituted and substituted 4-benzyl-1,3-dihydro-imidazole-2-thiones acting as specific or sel September 14, 2010
Compounds of Formula 1 ##STR00001## where the variables have the meaning defined in the specification are used to activate alpha.sub.2 adrenergic receptors. The compounds of Formula 1 are incorporated in pharmaceutical compositions and are used as medicaments in mammals, including human
7754768 Methods and compositions for modulating alpha adrenergic receptor activity July 13, 2010
Methods and compositions for the treatment of pain and intraocular pressure. Particularly disclosed are new compositions for the treatment of chronic pain, glaucoma and methods for their use.
7709507 Therapeutic fluoroethyl ureas May 4, 2010
Compounds of the formula ##STR00001## or a pharmaceutically acceptable salt thereof or a tautomer thereof, wherein A and B are as described herein, are useful for treating conditions afflicting mammals.
7683089 4-(Phenylmethyl and substituted phenylmethyl)-imidazole-2-thiones acting as specific alpha2 adre March 23, 2010
Compounds of Formula 1 ##STR00001## where the variables have the meaning defined in the specification are agonists of alpha.sub.2 adrenergic receptors. Several compounds of the disclosure are specific or selective to alpha.sub.2B and/or alpha.sub.2C adrenergic receptors in prefere
7612082 Prostaglandin EP.sub.4 antagonists November 3, 2009
Disclosed herein are methods and compositions related to compound 1 or compound 2 ##STR00001## or pharmaceutically acceptable salts, or prodrugs thereof, which are antagonists of a prostaglandin EP.sub.4 receptor, or are prostaglandin EP.sub.4 antagonists.
7598417 Substituted fluoroethyl ureas as alpha 2 adrenergic agents October 6, 2009
The present patent application is directed to novel fluoroethyl urea compounds and compositions and their therapeutic use in the treatment of pain and other conditions.
7598394 Process for the synthesis of imidazoles October 6, 2009
The present invention provides a process for the preparation of imidazoles by reacting a cyano compound with a silylalkylisocyanide compound. Such imidazoles are useful pharmacologically-active compounds and/or intermediates for the preparation of pharmacologically-active compounds.
7579481 Method of making imidazole-2-ones and 2-thiones August 25, 2009
A method of 4-substituted imidazole-2-ones and thiones which comprises reacting a methylene urea or methylene thiourea wherein said methylene is substituted with the 4-subsituent and a cyano or alkycarboxylate group to provide said 4-substituted imidazole 2-one or thione.
7569595 2-((2-thioxo-2,3-dihydro-1H-imidazol-4-yl)methyl)-3,4-dihydronaphthalen-1(- 2H)-one August 4, 2009
A compound of the formula ##STR00001## or a pharmaceutically acceptable salt thereof, is disclosed herein. Methods and compositions related thereto are also disclosed.
7531665 Kinase inhibitors for the treatment of disease May 12, 2009
The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.
7399868 4-(Heteroaryl-methyl and substituted heteroaryl-methyl)-imidazole-2-thiones acting as alpha2 adr July 15, 2008
Compounds of Formula 1 ##STR00001## where the variables have the meaning defined in the specification are agonists of alpha.sub.2 adrenergic receptors. Several compounds of the disclosure are specific or selective to alpha.sub.2B and/or alpha.sub.2C adrenergic receptors in preference
7396849 4-(Condensed cyclicmethyl)-imidazole-2-thiones acting as .alpha..sub.2 adrenergic agonists July 8, 2008
Compounds of Formula 1 ##STR00001## where the variables have the meaning defined in the specification are agonists of alpha.sub.2 adrenergic receptors. Several compounds of the disclosure are specific or selective to alpha.sub.2B and/or alpha.sub.2C adrenergic receptors in prefere
7358269 2-((2-Thioxo-2,3-dihydro-1H-imidazol-4-yl)methyl)-3,4-dihydronapthalen-1(2- H)-one April 15, 2008
A compound of the formula ##STR00001## or a pharmaceutically acceptable salt thereof, is disclosed herein. Methods and compositions related thereto are also disclosed.
7335803 Methods and compositions for modulating alpha adrenergic receptor activity February 26, 2008
Methods and compositions for the treatment of pain and intraocular pressure. Particularly disclosed are new compositions for the treatment of chronic pain, glaucoma and methods for their use.
7323485 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazo January 29, 2008
Compounds of Formula 1 ##STR00001## where X is S and the variables have the meaning defined in the specification are specific or selective to alpha.sub.2B and/or alpha.sub.2C adrenergic receptors in preference over alpha.sub.2A adrenergic receptors, and as such have no or only minimal
7294716 Process for preparing isomerically pure prodrugs of proton pump inhibitors November 13, 2007
Synthetic methods for preparing isomerically pure N-arylsulfonyl derivatives of proton pump inhibitors which include a substituted benzimidazole nucleus are shown by the synthetic schemes and experimental description.
7183324 2,3,4-substituted cyclopentanones as therapeutic agents February 27, 2007
Disclosed herein are compounds comprising ##STR00001## or a pharmaceutically acceptable salt or a prodrug thereof; wherein Y, A, B, J, and E are further described.Methods, compositions, and medicaments related thereto are also disclosed.
7183310 Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents February 27, 2007
A compound comprising ##STR00001## or a pharmaceutically acceptable salt or a prodrug thereof, having the groups described in detail herein is disclosed.Also disclosed herein are compounds comprising ##STR00002## or derivatives thereof, or pharmaceutically acceptable salts, tetrazoles,
7183305 Process for the synthesis of imidazoles February 27, 2007
The present invention provides a process for the preparation of imidazoles by reacting a cyano compound with a silylalkylisocyanide compound. Such imidazoles are useful pharmacologically-active compounds and/or intermediates for the preparation of pharmacologically-active compounds.
7115748 Method of making imidazole-2-thiones October 3, 2006
The present invention provides a method of making an imidazole-2-thione which comprises the steps of reacting a vicinal diamine with a compound having a thiocarbonyl moiety and oxidizing the resulting reaction product to obtain said imidazole-2-thione.
7101906 2,3,4-substituted cyclopentanones as therapeutic agents September 5, 2006
Disclosed herein are compounds comprising ##STR00001## or a pharmaceutically acceptable salt or a prodrug thereof, wherein a dashed line represents the presence or absence of a bond; Y is a carboxylic acid, sulfonic acid, or phosphonic acid functional group; or an amide or ester t
7101904 Cyclopentane heptan(ENE)OIC acid, 2-heteroarylalkenyl derivatives as therapeutic agents September 5, 2006
A compound ##STR00001## or a pharmaceutically acceptable salt or a prodrug thereof, wherein A, B, R.sup.1, R.sup.2, D, and E are defined herein. Use of the diseases for the treatment of diseases, and compositions and medicaments related thereto are also disclosed.
6841684 Imidiazoles having reduced side effects January 11, 2005
Methods and compounds for the treatment of conditions including pain, particularly chronic pain, glaucoma or elevated intraocular pressure with reduced cardiovascular or sedative side effects. Also included are methods of making and using such compounds.
6747025 Kinase inhibitors for the treatment of disease June 8, 2004
The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell poliferation.
6706747 Conformationally rigid bicyclic and adamantane derivatives useful as .alpha.2-adrenergic blockin March 16, 2004
A compound of formula I ##STR1##in which: ring A is one of the five alternative multi-cyclic rings as shown wherein a dotted line adjacent to a bond indicates that a single bond or a double bond may be present at that position; X is nitrogen, oxygen or sulfur; R is hydrogen, lower st
6569884 Conformationally rigid bicyclic and adamantane derivatives useful as .alpha.2-adrenergic blockin May 27, 2003
A compound of formula I ##STR1##in which: ring A is one of the five alternative multi-cyclic rings as shown wherein a dotted line adjacent to a bond indicates that a single bond or a double bond may be present at that position; X is nitrogen, oxygen or sulfur; R is hydrogen, lower st
1 2 3










 
 
  Recently Added Patents
Systems and methods for generating a hybrid text string from two or more text strings generated by multiple automated speech recognition systems
Dimmable LED light fixture having adjustable color temperature
Methods for predicting cardiac toxicity
Superagonistic anti-CD28 antibodies
Dental plier
Motion estimation for a video transcoder
Mobile device case with storage compartment
  Randomly Featured Patents
Analyte test strip
Saccharification enzymes from hyperthermophilic bacteria and processes for their production
2-Aminopyridine and 2-pyridone C-nucleosides, oligonucleotides comprising, and tests using the same oligonucleotides
Detector to determine the presence of an electrical signal in the presence of noise of predetermined characteristics
Vanadium addition to petroleum coke slurries to facilitate deslagging for controlled oxidation
Hand-held battery power sprayer
Processes for preparing a non-conductive substrate for electroplating
Cylinder for processing sheets of printing material and printing press having the cylinder
Polyamide from toluenediamine
Key holder